Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported 45 mins ago - Updated 45 mins ago - 1 reports

New Biomedicine and Biomedical Engineering Study Results from Vanderbilt University Described

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Biotechnology have been published. According to news originating from Nashville, Tennessee, by NewsRx correspondents, research stated, "The overexpression of ... [Published NewsRX - 45 mins ago]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Tau Therapeutics, LLC Collaborator Presents Data At American Association for Cancer Research

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event ... [Published BioSpace - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

AACR: Study identifies potential approach to overcome breast cancer resistance to HER2-targeted therapies

Resistance to a combination of HER2-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being ... [Published Ecancer Medicalscience - Apr 08 2014]
Entities: Tumor, Lapatinib, Herceptin
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Intermittent Lapatinib Hits Roadblock in HER2 Breast Cancer Study

In an attempt to fully inactivate the HER2 kinase, researchers found that intermittent oral lapatinib in patients with HER2-amplified breast cancer could be escalated up to 7,000 mg per day with no dose limiting toxicities, a treatment regimen first tested ... [Published Cancernetwork.com - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Trastuzumab emtansine: indication of major added benefit in 1 subpopulation

PUBLIC RELEASE DATE: 7-Apr-2014The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, ... [Published EurekAlert! - Apr 07 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

How I Treat Patients with HER2-Positive Metastatic Breast Cancer

SARA HURVITZ, MDImage ToolsIt is well recognized that the treatment of HER2-positive metastatic breast cancer has been revolutionized in the last 15 years—first by the introduction of trastuzumab; followed nine years later by lapatinib; and in the last ... [Published Oncology Times - Apr 06 2014]
Entities: Herceptin, T-DM1, Metastatic
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review - Abstract

The American Cancer Society estimates that 73 510 new cases of bladder cancer will be diagnosed and 15 000 deaths will result this year.The paper summarizes the clinical evidence for the use of platinum-based, non-platinum-based and new targeted biological ... [Published UroToday - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Letrozole–lapatinib combination did not improve outcomes in HR-positive, HER-2–negative breast cancer

The addition of lapatinib to letrozole did not significantly improve response rates in women with HR-positive, HER-2–negative operable breast cancer, according to results of a phase 2b study.However, patients with PIK3CA mutations were more likely to ... [Published Orthopedics Today - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

MERRIMACK PHARMACEUTICALS : "Combination Therapies Comprising Anti-Erbb3 Agents" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors ZHANG, Bo ( Lynnfield, MA ); McDonagh, Charlotte ( Winchester, MA ); Huhalov, Alexandra ( Cambridge, MA ), filed on August 30, 2013 , was made available ... [Published 4 Traders - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Revision: 19, Authorised

Entities: Tyverb, Lapatinib
First reported Mar 30 2014 - Updated Mar 30 2014 - 1 reports

Tiziana Life Sciences to Raise $3.3 Million in London IPO

Tiziana Life Sciences Plc, a U.K. developer of an experimental treatment for late-stage breast cancer, is planning to raise 2 million pounds ($3.3 million) in a London initial public offering.Tiziana aims to sell 16.7 million shares for 12 pence each ... [Published Bloomberg - Mar 30 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell ...

While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of these drugs. microRNAs have potential as ... [Published 7thSpace - Mar 24 2014]

Quotes

...According to news originating from Nashville, Tennessee, by NewsRx correspondents, research stated, "The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance."
NEXT ARTICLE More From BioPortfolio on "AACR: Study identifies potential approach to overcome breast cancer resistance to HER2-targeted therapies"
Professor Moncada said: "The University of Manchester has an outstanding history of research and innovation and there are currently many exciting things happening within the field of cancer. It’s a fantastic time to work in this area of research and I am delighted to be leading a team of scientists and clinicians which has already made a big contribution to the understanding and management of this very important disease.”"
...as Src inhibitors, or drug combinations that would inhibit the same spectrum of targets," said Samuel D Waksal, Ph D , Chairman and CEO of Kadmon. "Further, as an effective penetrant of the blood brain barrier, KD019 holds potential in treating tumors metastasized to the brain -- an area where currently approved therapies demonstrate little benefit. We look forward to initiating clinical trials of KD019 in women with previously treated, Src- and HER2-positive, metastatic breast cancer, both with and without metastases to the brain, in the near future."

More Content

All (57) | News (56) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New Biomedicine and Biomedical Engineering Stud... [Published NewsRX - 45 mins ago]
HER2 Targeting in Early Breast Cancer: More Opt... [Published Cancernetwork.com - 22 hours ago]
Deep Targeted Sequencing for Breast Cancer Care [Published General Medicine eJournal - Apr 15 2014]
Tau Therapeutics, LLC Collaborator Presents Dat... [Published BioSpace - Apr 11 2014]
Tau Therapeutics Collaborator Presents Data at ... [Published BioPortfolio - Apr 11 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
AACR: Study identifies potential approach to ov... [Published Ecancer Medicalscience - Apr 08 2014]
AACR Study identifies potential approach to ove... [Published BioPortfolio - Apr 08 2014]
New Director of Institute for Cancer Sciences [Published University of Manchester - Apr 08 2014]
Intermittent Lapatinib Hits Roadblock in HER2 B... [Published Cancernetwork.com - Apr 08 2014]
Trastuzumab emtansine: indication of major adde... [Published EurekAlert! - Apr 07 2014]
KADMON CORPORATION : Presents Preclinical Resul... [Published 4 Traders - Apr 07 2014]
Therapies for Early-stage Lung Cancer [Published Diabetes Care - Apr 07 2014]
How I Treat Patients with HER2-Positive Metasta... [Published Oncology Times - Apr 06 2014]
Glioblastomas - a personalised future? [Published PMLive - Apr 04 2014]
Chemotherapeutic and targeted biological agents... [Published UroToday - Apr 04 2014]
Letrozole–lapatinib combination did not improve... [Published Orthopedics Today - Apr 03 2014]
MERRIMACK PHARMACEUTICALS : "Combination Therap... [Published 4 Traders - Apr 03 2014]
Genomic Testing: A Powerful Weapon Against Brea... [Published Daily Rx - Apr 02 2014]
Allosteric AKT Inhibitor and Trastuzumab in HER... [Published General Medicine eJournal - Apr 01 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
Breast cancer drug therapy "set to become more ... [Published Pharma Times - Mar 31 2014]
Tiziana Life Sciences to Raise $3.3 Million in ... [Published Bloomberg - Mar 30 2014]
Factors driving oncologists’ prescribing decisi... [Published Pharma Letter - Mar 28 2014]
Report: Breast Cancer Treatment Will Become Mor... [Published P&T Community - Mar 26 2014]
"CANCER TREATMENT USING TYROSINE KINASE AND NF-... [Published Pharmacy Choice - Mar 26 2014]
miR-630 targets IGF1R to regulate response to H... [Published 7thSpace - Mar 24 2014]
Antibody-Drug Conjugates and T-DM1 [Published OncLive - Mar 21 2014]
Hormone Refractory Breast Cancer Global Clinica... [Published BioPortfolio - Mar 21 2014]
Proteomic Advances Hold Promise for Precision M... [Published American Journal of Managed Care - Mar 20 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.